Regorafenib Plus FOLFIRI With Irinotecan Dose Escalated in Patients With Previously Treated Metastatic Colorectal Cancer

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE2

Total Enrollment

153 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-02-26

Study Completion Date

2021-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A prospective, multicenter, randomized in a 2:1 ratio, controlled, clinical trial with two parallel arms will be conducted to compare irinotecan dose escalated FOLFIRI according to UGT1A1 genotyping plus 120 mg regorafenib with 120 mg regorafenib alone in previously treated patients with metastatic colorectal cancer (mCRC).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Metastatic Colorectal Cancer Treated With Regorafenib and FOLFIRI

NCT03698253

Colorectal Cancer

COMPLETED NA

Second-line FOLFOX With or Without Regorafenib in mCRC Patients Failed to First-line Irinotecan Plus Fluoropyrimidines

NCT01786538

Metastatic Colorectal Cancer

WITHDRAWN PHASE3

Phase II Trial of FOLFOXIGIL Versus FOLFOXIRI as First-line Therapy in Patients With mCRC

NCT03222089

Metastatic Colorectal Cancer

WITHDRAWN PHASE2

A Study of Aflibercept Versus Placebo With FOLFIRI in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin Chemotherapy

NCT01661270

Colorectal Cancer Metastatic

COMPLETED PHASE3

Fruquintinib With or Without HAI-FOLFOX for Refractory Colorectal Cancer

NCT06441565

Colorectal Cancer

RECRUITING PHASE2/PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Primary objective:

Progression-free survival

Secondary objective:

Overall survival, best objective response, disease control rate, time to progression, duration of treatment and adverse events

Number of Subjects: 153 patients with metastatic colorectal cancer treated with regorafenib and FOLFIRI as a third- or fourth-line setting.

Plan of the Study:

1. This is a prospective, multicenter, randomized in a 2:1 ratio, controlled study.
2. Study Schedule Study date: the time getting approval letter issued by both regulatory authority and institutional review board (IRB). Duration of the study: 4 years.
3. Duration of Treatment: Treatment was administered until disease progressed.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Metastatic Colorectal Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Regorafenib plus FOLFIRI

Regimen for treatment consists of irinotecan (180 mg/m2 as a 120-min IV infusion for UGT1A1 genotyping (TA6/TA6) and UGT1A1 genotyping (TA6/TA7); 120 mg/m2 as a 120-min IV infusion for UGT1A1 genotyping (TA7/TA7)), followed by Leucovorin (400 mg/m2 IV infusion over 2 hours), and fluorouracil (5-FU) (2800 mg/m2 IV infusion over a 46-hour period), repeated every 2 weeks.

After every 2 cycles of each different dose of irinotecan, if adverse events (AEs) are under the grade 2, we will escalate the dose of 30 mg/m2. The estimated maximal dose of irinotecan is 260 mg/m2 for UGT1A1 genotyping (TA6/TA6); 240 mg/m2 for UGT1A1 genotyping (TA6/TA7); 180 mg/m2 for UGT1A1 genotyping (TA7/TA7).

Regorafenib is administered at adjusted dosage of 120 mg daily for 3 weeks in a 4-week cycle.

Group Type EXPERIMENTAL

Regorafenib

Intervention Type DRUG

Regorafenib is administered at dose of 120 mg daily for 3 weeks in a 4-week cycle

UGT1A1 genotyping (TA6/TA6)

Intervention Type GENETIC

The dosage of irinotecan in FOLFIRI is escalated from 180mg/m2 to 260 mg/m2

UGT1A1 genotyping (TA6/TA7)

Intervention Type GENETIC

The dosage of irinotecan in FOLFIRI is escalated from 180mg/m2 to 240 mg/m2

UGT1A1 genotyping (TA7/TA7)

Intervention Type GENETIC

The dosage of irinotecan in FOLFIRI is escalated from 120mg/m2 to180 mg/m2

Leucovorin and 5-FU

Intervention Type DRUG

Leucovorin (400 mg/m2 IV infusion over 2 hours), and 5-FU (2800 mg/m2 IV infusion over a 46-hour period)

Regorafenib

Regorafenib is administered at adjusted dosage of 120 mg daily for 3 weeks in a 4-week cycle.

Group Type ACTIVE_COMPARATOR

Regorafenib

Intervention Type DRUG

Regorafenib is administered at dose of 120 mg daily for 3 weeks in a 4-week cycle

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Regorafenib

Regorafenib is administered at dose of 120 mg daily for 3 weeks in a 4-week cycle

Intervention Type DRUG

UGT1A1 genotyping (TA6/TA6)

The dosage of irinotecan in FOLFIRI is escalated from 180mg/m2 to 260 mg/m2

Intervention Type GENETIC

UGT1A1 genotyping (TA6/TA7)

The dosage of irinotecan in FOLFIRI is escalated from 180mg/m2 to 240 mg/m2

Intervention Type GENETIC

UGT1A1 genotyping (TA7/TA7)

The dosage of irinotecan in FOLFIRI is escalated from 120mg/m2 to180 mg/m2

Intervention Type GENETIC

Leucovorin and 5-FU

Leucovorin (400 mg/m2 IV infusion over 2 hours), and 5-FU (2800 mg/m2 IV infusion over a 46-hour period)

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

stivarga

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Cyto-/histological confirmed mCRC
2. Patients who have been previously treated with, or are not considered candidates for, other locally approved standard treatment(s) and for whom the decision has been made per investigator's routine treatment practice to prescribe regorafenib as 3rd line (RAS mutant) or 4th line (RAS wild type) therapy
3. Aged no less than 20 years, at the time of acquisition of informed consent
4. Eastern Cooperative Oncology Group (ECOG) performance score of 0-1
5. Patients with measurable or non-measurable disease in the colon or rectum, according to RECIST criteria version 1.1
6. Life expectancy more than 12 weeks
7. Women with childbearing potential must agree to perform adequate contraception measures since informed consent till a least 12 weeks after the last study drug administration.

The investigators or designee are requested to advise the patient to achieve adequate birth control.
8. Adequate organ and bone marrow function as defined below:

* Total bilirubin \<= 1.5 x the upper limit of normal (ULN)
* Alanine amino-transferase (ALT) and aspartate amino-transferase (AST) \<= 2.5 x ULN (\<= 5 x ULN for patients with liver metastases)
* Alkaline phosphatase (ALP) \<= 2.5 x ULN (\<= 5 x ULN for patients with liver metastases)
* Amylase and lipase \<= 1.5 x ULN
* Serum creatinine \<= 1.5 x ULN
* Glomerular filtration rate (GFR) \>= 30 mL/min/1.73 m2, according to the modified diet in renal disease (MDRD) abbreviated formula
* International normalized ratio (INR)/partial thromboplastin time (PTT) \<= 1.5 x ULN
* Platelet counts \>= 100,000/mm3
* Hemoglobin level \>= 9 g/dL
* Absolute neutrophil counts \>= 1,500/mm3
9. Ability to understand and willingness to sign written Informed Consent Form (ICF)

Exclusion Criteria

1. Prior treatment with regorafenib within 28 days
2. Other concurrent cancer or prior treatment for other carcinomas within the last five years, except curatively treated non-melanoma skin cancer, superficial bladder tumors, and cervical cancer in-situ
3. Extended field radiotherapy within 28 days or limited radiotherapy within 14 days prior to randomization
4. Major surgery within 28 days prior to start of study treatment (diagnostic biopsy, laparotomy, line placement is not considered as major surgery)
5. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, myocardial infarction in the past 12 months, active gastrointestinal bleeding, central nervous system disorders or psychiatric illness/social situation that would limit compliance with study requirements or judged to be ineligible for the study by the investigator
6. History of myocardial infarction, deep venous or arterial thrombosis, or cardiovascular accident (CVA) during the last 6 months
7. Uncontrolled cardiac arrhythmias, unstable angina, or newly-onset angina within 3 months prior to study entry
8. Uncontrolled hypertension despite optimal management (systolic blood pressure \> 150 mmHg or diastolic pressure \> 90 mmHg)
9. Patients with known central nervous system (CNS) metastases
10. Having received any investigational agents or participating in any investigational drug study within 4 weeks prior to study enrollment
11. Pregnant or breast-feeding female (a pregnancy test must be performed on all female patients with child-bearing potential within 7 days of treatment initiation, and the result must be negative)
12. Inability to take oral medications
13. Poor compliance as judged by the investigator

Minimum Eligible Age

20 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No